Malignant News and Research

RSS

$3.9 million Challenge grant for Thomas Jefferson researchers

Four researchers from Thomas Jefferson University have received $3.9 million in Challenge grant funds as part of the American Recovery and Reinvestment Act.

3 Nov 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Researchers report preclinical results of a novel PET biomarker designed to detect malignant breast tumors

Researchers at Thomas Jefferson University in Philadelphia, PA, supported in part by NuView Life Sciences, have published an article in the Journal of Nuclear Medicine reporting preclinical results of a novel PET biomarker designed to selectively detect malignant breast tumors.

30 Oct 2009

Study: HSP inhibitor could stop tumor formation and extend survival

Like yoga for office drones, cells do have coping strategies for stress. Heat, lack of nutrients, oxygen radicals - all can wreak havoc on the delicate internal components of a cell, potentially damaging it beyond repair. Proteins called HSPs (heat shock proteins) allow cells to survive stress-induced damage. Scientists have long studied how HSPs work in order to harness their therapeutic potential.

30 Oct 2009

PEM scanners outperform MRI in detecting breast cancer

An NIH-sponsored, multi-year study of hundreds of women diagnosed with breast cancer found that Positron Emission Mammography (PEM) scanners significantly outperform MRI when differentiating between benign and cancerous lesions.

30 Oct 2009

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

TomoTherapy Incorporated announced today that several clinical presentations at the American Society for Radiation Oncology's 51st ASTRO Annual Meeting -- November 1-5, 2009 in Chicago -- will showcase the use of the TomoTherapy® radiation therapy platform as a vital component in the combined modality approach to treating cancer.

30 Oct 2009

World’s first Cesium-131 lung implants performed

IsoRay, Inc. announced today that starting on August 12, 2009, Dr. Bhupesh Parashar from the Department of Radiation Oncology, and Dr. Nasser Altorki of the Department of Cardiothoracic Surgery at Weill Cornell Medical Center performed the world’s first Cesium-131 lung implants.

29 Oct 2009

Novian Health and Rose Medical Center sign an agreement to provide Novilase laser treatment to treat breast lumps

Novian Health, manufacturer of Novilase™ Breast Therapy for benign breast tumors, announced an agreement with Rose Medical Center for Rose to provide the Novilase laser treatment to treat breast lumps.

29 Oct 2009

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Many pediatric and adolescent patients who received second-generation antipsychotic medications experienced significant weight gain, along with varied adverse effects on cholesterol and triglyceride levels and other metabolic measures, according to a study in the October 28 issue of JAMA.

28 Oct 2009

Multidisciplinary center to be launched for treatment of advanced liver disease

Distinguished transplant and cancer surgeon, Alan Hemming, MD, has been recruited to the University of California, School of Medicine to launch a multidisciplinary center for the treatment of advanced liver disease at the UC San Diego Medical Center and Moores UCSD Cancer Center.

28 Oct 2009

Combination of treatments for breast cancer

At the end of a 10-year, coast-to-coast study of women with an unusual form of breast cancer, Richard J. Barth Jr., M.D., and three fellow researchers are making the case for a particular combination of treatments to stop the tumors in their tracks.

27 Oct 2009

First child with a surgically implanted artificial humerus doing well after a year

When little Mark Blinder was diagnosed with a rare bone cancer, doctors at Lucile Packard Children's Hospital gave his parents three agonizing options: amputate the affected arm at the shoulder, irradiate the tumor and risk a second malignancy, or try a limb-preserving surgery that had never been attempted in a toddler.

27 Oct 2009

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.

27 Oct 2009

New significant tool to improve the quality of care for patients with brain tumors released

While the nation is debating how best to reform healthcare, the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) announce a new significant tool to improve the quality of care for patients who suffer from brain tumors.

27 Oct 2009

Results from Phase I dose-escalation study of AT-101 announced

Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).

26 Oct 2009

New urine tests may help predict kidney problems post surgery

Two studies presented at this week's Annual Meeting of the American Society of Anesthesiologists offer new information as to how physicians might better determine which surgical patients may be at risk for developing kidney injury after surgery.

26 Oct 2009

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

TransMolecular, Inc., a developer of innovative oncology drugs through targeted delivery technologies, today announced final results from its Phase 2 clinical study comparing the toxicity and overall survival of three versus six intracavitary injections of its anti-cancer compound 131I-TM601 in the treatment of recurrent malignant glioma.

24 Oct 2009

Malignant News and Research

$3.9 million Challenge grant for Thomas Jefferson researchers

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Researchers report preclinical results of a novel PET biomarker designed to detect malignant breast tumors

Study: HSP inhibitor could stop tumor formation and extend survival

PEM scanners outperform MRI in detecting breast cancer

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

World’s first Cesium-131 lung implants performed

Novian Health and Rose Medical Center sign an agreement to provide Novilase laser treatment to treat breast lumps

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Multidisciplinary center to be launched for treatment of advanced liver disease

Combination of treatments for breast cancer

First child with a surgically implanted artificial humerus doing well after a year

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

New significant tool to improve the quality of care for patients with brain tumors released

Results from Phase I dose-escalation study of AT-101 announced

New urine tests may help predict kidney problems post surgery

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

Cord Blood America updates progress of its Las Vegas cryogenic facility on MoneyTV

Schering-Plough announces 2009 third quarter financial results

£17,000 grant to university researcher for breast cancer research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News